195 related articles for article (PubMed ID: 31676270)
1. Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates.
Tada M; Aoyama M; Ishii-Watabe A
J Pharm Sci; 2020 Jan; 109(1):576-583. PubMed ID: 31676270
[TBL] [Abstract][Full Text] [Related]
2. A Cell-Based Reporter Assay Measuring the Activation of Fc Gamma Receptors Induced by Therapeutic Monoclonal Antibodies.
Aoyama M; Tada M; Ishii-Watabe A
Methods Mol Biol; 2019; 1904():423-429. PubMed ID: 30539484
[TBL] [Abstract][Full Text] [Related]
3. [Characterization of Therapeutic Monoclonal Antibodies by Using FcγR-expressing Reporter Cell Lines].
Tada M; Ishii-Watabe A
Yakugaku Zasshi; 2017; 137(7):837-843. PubMed ID: 28674297
[TBL] [Abstract][Full Text] [Related]
4. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.
Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A
Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908
[TBL] [Abstract][Full Text] [Related]
5. Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.
Wines BD; Trist HM; Esparon S; Impey RE; Mackay GA; Andrews RK; Soares da Costa TP; Pietersz GA; Baker RI; Hogarth PM
Front Immunol; 2021; 12():666813. PubMed ID: 34759915
[TBL] [Abstract][Full Text] [Related]
6. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
7. Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes.
Bailey EM; Choudhury A; Vuppula H; Ortiz DF; Schaeck J; Manning AM; Bosques CJ; Hoppe AD
Front Immunol; 2020; 11():617767. PubMed ID: 33679705
[TBL] [Abstract][Full Text] [Related]
8. Development of cell-based assay for predictively evaluating the FcγR-mediated human immune cell activation by therapeutic monoclonal antibodies.
Takakura M; Tada M; Ishii-Watabe A
Biochem Biophys Res Commun; 2017 Mar; 485(1):189-194. PubMed ID: 28196745
[TBL] [Abstract][Full Text] [Related]
9. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.
Bournazos S; Chow SK; Abboud N; Casadevall A; Ravetch JV
J Clin Invest; 2014 Feb; 124(2):725-9. PubMed ID: 24401277
[TBL] [Abstract][Full Text] [Related]
10. Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies.
Tada M; Ishii-Watabe A; Suzuki T; Kawasaki N
PLoS One; 2014; 9(4):e95787. PubMed ID: 24752341
[TBL] [Abstract][Full Text] [Related]
11. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
13. Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: Implications for Measuring Fc Dependent Antibody Functions.
Lopez E; Scott NE; Wines BD; Hogarth PM; Wheatley AK; Kent SJ; Chung AW
Front Immunol; 2019; 10():2415. PubMed ID: 31681303
[TBL] [Abstract][Full Text] [Related]
14. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
Front Immunol; 2019; 10():390. PubMed ID: 30899264
[TBL] [Abstract][Full Text] [Related]
15. Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode.
Weber F; Bohrmann B; Niewoehner J; Fischer JAA; Rueger P; Tiefenthaler G; Moelleken J; Bujotzek A; Brady K; Singer T; Ebeling M; Iglesias A; Freskgård PO
Cell Rep; 2018 Jan; 22(1):149-162. PubMed ID: 29298417
[TBL] [Abstract][Full Text] [Related]
16. Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.
Van den Hoecke S; Ehrhardt K; Kolpe A; El Bakkouri K; Deng L; Grootaert H; Schoonooghe S; Smet A; Bentahir M; Roose K; Schotsaert M; Schepens B; Callewaert N; Nimmerjahn F; Staeheli P; Hengel H; Saelens X
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077656
[TBL] [Abstract][Full Text] [Related]
17. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
[TBL] [Abstract][Full Text] [Related]
18. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
19. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
20. Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.
Yu X; Menard M; Prechl J; Bhakta V; Sheffield WP; Lazarus AH
Blood; 2016 Jan; 127(1):132-8. PubMed ID: 26500340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
